This article was originally published in The Rose Sheet
Skin-Care Devices Are Next $1 Bil. Market
You may also be interested in...
The decision to close Clarisonic follows a €234m impairment charge recorded in 2016 and comes as L’Oreal faces tough strategic decisions in a global economy ravaged by the COVID-19 crisis.
An FDA warning letter to Quasar Bio-Tech suggests the marketer of Baby Quasar and Quasar MD lacks correct 510(k) device clearance and is improperly marketing its home-use skin-care device products. Quasar maintains it holds the correct clearances, and that FDA may be confused by its product nomenclature.